Shinichi Sakamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinichi Sakamoto has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Tomohiko Ichikawa
Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
5 shared publicationsHiroyoshi Suzuki
Department of Urology, Chiba University Hospital, Chiba-city, Japan; Department of Urology, Toho University Medical Center Sakura Hospital, Sakura, Japan; Department of Urology, Yokohama Rosai Hospital, Yokohama City, Japan; Department of Urology, Japan Community Health Care Organization Tokyo Shinjuku, Tokyo, Japan
3 shared publicationsKoichiro Akakura
Department of Urology, Chiba University Hospital, Chiba-city, Japan; Department of Urology, Toho University Medical Center Sakura Hospital, Sakura, Japan; Department of Urology, Yokohama Rosai Hospital, Yokohama City, Japan; Department of Urology, Japan Community Health Care Organization Tokyo Shinjuku, Tokyo, Japan
3 shared publicationsKoji Kawamura
Department of Urology, Chiba University Hospital, Chiba-city, Japan; Department of Urology, Toho University Medical Center Sakura Hospital, Sakura, Japan; Department of Urology, Yokohama Rosai Hospital, Yokohama City, Japan; Department of Urology, Japan Community Health Care Organization Tokyo Shinjuku, Tokyo, Japan
3 shared publicationsNaoki Nihei
Department of Urology, Chiba University Hospital, Chiba-city, Japan; Department of Urology, Toho University Medical Center Sakura Hospital, Sakura, Japan; Department of Urology, Yokohama Rosai Hospital, Yokohama City, Japan; Department of Urology, Japan Community Health Care Organization Tokyo Shinjuku, Tokyo, Japan
3 shared publicationsTakashi Imamoto
Department of Urology, Chiba University Hospital, Chiba-city, Japan; Department of Urology, Toho University Medical Center Sakura Hospital, Sakura, Japan; Department of Urology, Yokohama Rosai Hospital, Yokohama City, Japan; Department of Urology, Japan Community Health Care Organization Tokyo Shinjuku, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 23 June 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 848
Apparent diffusion coefficient value for estimating clinicohistological factors in bladder cancer including infiltration style and lymphatic invasion
To evaluate a role of apparent diffusion coefficient (ADC) values measured from diffusion-weighted imaging we investigated its association with clinicopathological tumor characteristics of bladder cancer. Diffusion-weighted MRI at 1.5 Tesla using b-values of 0, 1000 s/mm2 was taken before transurethral resection by 114 bladder urothelial tumor patients. ADC value was measured and its relationship with pathological factors including T stage, tumor grade, infiltration style (INF) and lymphatic invasion (ly) was analyzed. Median ADC value was significantly lower in Grade 3 than in Grade 1 (P < 0.001) or in Grade 2 (P = 0.002), in INFb than in INFa (P = 0.004), in INFc than in INFa (P < 0.001), in ly1 than in ly0 (P < 0.001) and lower in T2≦ than in T1≧ (P < 0.001), respectively. Receiver operating curve demonstrated the accuracy of detecting muscle invasive bladder cancer or ly+ by using area under curve (AUC), showing 0.758 and 0.748. ADC value is likely to serve as a useful biomarker showing clinicopathological characterictics of bladder cancer.
- 23 June 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 848
Open AccessApparent diffusion coefficient value for estimating clinicohistological factors in bladder cancer including infiltration style and lymphatic invasion
To evaluate a role of apparent diffusion coefficient (ADC) values measured from diffusion-weighted imaging we investigated its association with clinicopathological tumor characteristics of bladder cancer. Diffusion-weighted MRI at 1.5 Tesla using b-values of 0, 1000 s/mm2 was taken before transurethral resection by 114 bladder urothelial tumor patients. ADC value was measured and its relationship with pathological factors including T stage, tumor grade, infiltration style (INF) and lymphatic invasion (ly) was analyzed. Median ADC value was significantly lower in Grade 3 than in Grade 1 (P < 0.001) or in Grade 2 (P = 0.002), in INFb than in INFa (P = 0.004), in INFc than in INFa (P < 0.001), in ly1 than in ly0 (P < 0.001) and lower in T2≦ than in T1≧ (P < 0.001), respectively. Receiver operating curve demonstrated the accuracy of detecting muscle invasive bladder cancer or ly+ by using area under curve (AUC), showing 0.758 and 0.748. ADC value is likely to serve as a useful biomarker showing clinicopathological characterictics of bladder cancer.
- 20 June 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (8) , 653
Editorial Comment to Androgen receptor splice variant 7 in castration‐resistant prostate cancer: Clinical considerations
- 20 June 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (8) , 653
Editorial Comment to Androgen receptor splice variant 7 in castration‐resistant prostate cancer: Clinical considerations
- 20 June 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (8) , 666
Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
- 20 June 2016
- Published by Wiley in International Journal of Urology
- Vol. 23 (8) , 666
Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
- 1 May 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (5) , 1588-1597
Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells
Cancer cells require massive amounts of amino acids for survival. LAT1 (L-type amino acid transporter 1) transports essential amino acids, including leucine, which trigger the downstream mTOR (mammalian target of rapamycin) pathway. We examined the association between androgen receptor and LAT1, and the association between LAT1 expression and the acquisition of castration resistance. Western blot and real-time polymerase chain reaction were performed to study protein and mRNA expression. siRNA was used to knock down target genes. A total of 92 prostate biopsy specimens of patients who underwent androgen deprivation therapy were used for immunohistochemical analyses. Cox hazard proportional models and the Kaplan-Meier method were used for statistical analyses. LAT1 was highly expressed in hormone resistant prostate cancer cell lines. Knockdown of LAT1 in LNCaP and C4-2 cells significantly suppressed cell proliferation, migration and invasion. Androgen receptor siRNA or androgen receptor blocking through bicalutamide (10 μM) or MDV3100 (10 μM) significantly increased LAT1 expression (p <0.01). Treatment with dihydrotestosterone (0.1 to 10 nM) reduced LAT1 expression in a dose dependent manner (p <0.01). Bicalutamide/MDV3100 plus siLAT1 synergistically suppressed prostate cancer cell proliferation compared to single inhibition by androgen receptor or LAT1 (p <0.01). High LAT1 expression correlated with significantly shorter prostate specific antigen recurrence-free survival in patients receiving androgen deprivation therapy (p <0.0001). LAT1 expression was an independent predictor of castration resistance on multivariate analysis (HR 3.56, p = 0.0133). The current data may indicate a novel mechanism to acquire castration resistance through activation of the amino acid transporter LAT1.
- 1 May 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (5) , 1588-1597
Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells
Cancer cells require massive amounts of amino acids for survival. LAT1 (L-type amino acid transporter 1) transports essential amino acids, including leucine, which trigger the downstream mTOR (mammalian target of rapamycin) pathway. We examined the association between androgen receptor and LAT1, and the association between LAT1 expression and the acquisition of castration resistance. Western blot and real-time polymerase chain reaction were performed to study protein and mRNA expression. siRNA was used to knock down target genes. A total of 92 prostate biopsy specimens of patients who underwent androgen deprivation therapy were used for immunohistochemical analyses. Cox hazard proportional models and the Kaplan-Meier method were used for statistical analyses. LAT1 was highly expressed in hormone resistant prostate cancer cell lines. Knockdown of LAT1 in LNCaP and C4-2 cells significantly suppressed cell proliferation, migration and invasion. Androgen receptor siRNA or androgen receptor blocking through bicalutamide (10 μM) or MDV3100 (10 μM) significantly increased LAT1 expression (p <0.01). Treatment with dihydrotestosterone (0.1 to 10 nM) reduced LAT1 expression in a dose dependent manner (p <0.01). Bicalutamide/MDV3100 plus siLAT1 synergistically suppressed prostate cancer cell proliferation compared to single inhibition by androgen receptor or LAT1 (p <0.01). High LAT1 expression correlated with significantly shorter prostate specific antigen recurrence-free survival in patients receiving androgen deprivation therapy (p <0.0001). LAT1 expression was an independent predictor of castration resistance on multivariate analysis (HR 3.56, p = 0.0133). The current data may indicate a novel mechanism to acquire castration resistance through activation of the amino acid transporter LAT1.
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 194 (5) , 1264-1270
Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade
We examined the clinical significance of long-term serum testosterone monitoring to predict the prognosis of patients with prostate cancer treated with combined androgen blockade. We retrospectively analyzed the records of 225 patients who underwent combined androgen blockade as first line therapy for prostate cancer. The prognostic values of testosterone and other clinical factors were evaluated with respect to prostate specific antigen progression-free and overall survival. Median patient age was 73.0 years, median prostate specific antigen was 42.6 ng/ml and median followup was 45.8 months. No variable associated with testosterone was predictive of progression-free survival. With regard to overall survival on univariate analysis nadir testosterone less than 16 ng/dl (p = 0.0190), less than 20 ng/dl (p = 0.0020) and less than 32 ng/dl (p = 0.0146) were significant together with other clinical factors. In contrast, nadir testosterone less than 8 and less than 12 ng/dl were not significant. Multivariate analysis showed that nadir testosterone less than 20 ng/dl was the significant prognostic factor (p = 0.0048). In addition, time to nadir testosterone was about 1 year (11.3 months). Patients were divided into rapid and slow types based on time to testosterone less than 20 ng/dl before and after 6 months, respectively. No significant difference in overall survival was observed between the 2 types. The current results suggest that the critical factor for prognosis was not a rapid decrease but whether nadir testosterone achieved a level of less than 20 ng/dl. Nadir testosterone 20 ng/dl was the most significant cutoff level for overall survival in Japanese patients with prostate cancer treated with combined androgen blockade.
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 194 (5) , 1264-1270
Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade
We examined the clinical significance of long-term serum testosterone monitoring to predict the prognosis of patients with prostate cancer treated with combined androgen blockade. We retrospectively analyzed the records of 225 patients who underwent combined androgen blockade as first line therapy for prostate cancer. The prognostic values of testosterone and other clinical factors were evaluated with respect to prostate specific antigen progression-free and overall survival. Median patient age was 73.0 years, median prostate specific antigen was 42.6 ng/ml and median followup was 45.8 months. No variable associated with testosterone was predictive of progression-free survival. With regard to overall survival on univariate analysis nadir testosterone less than 16 ng/dl (p = 0.0190), less than 20 ng/dl (p = 0.0020) and less than 32 ng/dl (p = 0.0146) were significant together with other clinical factors. In contrast, nadir testosterone less than 8 and less than 12 ng/dl were not significant. Multivariate analysis showed that nadir testosterone less than 20 ng/dl was the significant prognostic factor (p = 0.0048). In addition, time to nadir testosterone was about 1 year (11.3 months). Patients were divided into rapid and slow types based on time to testosterone less than 20 ng/dl before and after 6 months, respectively. No significant difference in overall survival was observed between the 2 types. The current results suggest that the critical factor for prognosis was not a rapid decrease but whether nadir testosterone achieved a level of less than 20 ng/dl. Nadir testosterone 20 ng/dl was the most significant cutoff level for overall survival in Japanese patients with prostate cancer treated with combined androgen blockade.
- 8 October 2015
- Published by Wiley in International Journal of Urology
- Vol. 23 (1) , 49-54
Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men
Objectives: To validate the ability of contemporary active surveillance protocols to predict pathologically insignificant prostate cancer among Asian men undergoing radical prostatectomy.Methods: We retrospectively reviewed data on 132 patients eligible for any active surveillance criteria out of 450 patients that underwent radical prostatectomy at several institutions between 2006 and 2013. We validated the ability of seven contemporary active surveillance protocols to predict pathologically insignificant prostate cancer. Traditional and updated criteria to define pathologically insignificant prostate cancer were used. Predictive factors for pathologically insignificant prostate cancer were determined by logistic regression analysis.Results: The predictive rate for updated pathologically insignificant prostate cancer of respective active surveillance criteria was 51% for Johns Hopkins Medical Institution, 41% for Prostate Cancer Research International: Active Surveillance Study, 39% for University of Miami, 32% for University of California, San Francisco, 32% for Memorial Sloan‐Kettering Cancer Center, 31% for Kakehi and 27% for University of Toronto. Predictive rates for pathologically insignificant prostate cancer in Asian men were far lower than in USA men. On multivariate analysis, predictive factors of updated pathologically insignificant cancer was prostate volume (odds ratio 1.07, P = 0.004). By adding prostate volume to Prostate Cancer Research International: Active Surveillance Study criteria, the predictive rate for updated insignificant prostate cancer was improved up to 66.7%.Conclusions: Active surveillance can be carried out considering the clinical characteristics of prostate cancers depending on ethnicity, as current active surveillance criteria seem to have a lower predictive ability value of insignificant prostate cancer in Asian men compared with men in Western countries.
- 8 October 2015
- Published by Wiley in International Journal of Urology
- Vol. 23 (1) , 49-54
Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men
Objectives: To validate the ability of contemporary active surveillance protocols to predict pathologically insignificant prostate cancer among Asian men undergoing radical prostatectomy.Methods: We retrospectively reviewed data on 132 patients eligible for any active surveillance criteria out of 450 patients that underwent radical prostatectomy at several institutions between 2006 and 2013. We validated the ability of seven contemporary active surveillance protocols to predict pathologically insignificant prostate cancer. Traditional and updated criteria to define pathologically insignificant prostate cancer were used. Predictive factors for pathologically insignificant prostate cancer were determined by logistic regression analysis.Results: The predictive rate for updated pathologically insignificant prostate cancer of respective active surveillance criteria was 51% for Johns Hopkins Medical Institution, 41% for Prostate Cancer Research International: Active Surveillance Study, 39% for University of Miami, 32% for University of California, San Francisco, 32% for Memorial Sloan‐Kettering Cancer Center, 31% for Kakehi and 27% for University of Toronto. Predictive rates for pathologically insignificant prostate cancer in Asian men were far lower than in USA men. On multivariate analysis, predictive factors of updated pathologically insignificant cancer was prostate volume (odds ratio 1.07, P = 0.004). By adding prostate volume to Prostate Cancer Research International: Active Surveillance Study criteria, the predictive rate for updated insignificant prostate cancer was improved up to 66.7%.Conclusions: Active surveillance can be carried out considering the clinical characteristics of prostate cancers depending on ethnicity, as current active surveillance criteria seem to have a lower predictive ability value of insignificant prostate cancer in Asian men compared with men in Western countries.
- 8 June 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (7) , 637
Editorial Comment to Stenting for malignant ureteral obstruction: Tandem, metal or metal‐mesh stents
- 8 June 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (7) , 637
Editorial Comment to Stenting for malignant ureteral obstruction: Tandem, metal or metal‐mesh stents
- 9 April 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (6) , 532-3
Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
- 9 April 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (6) , 532-3
Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
- 11 February 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (3) , 252-3
Editorial comment to Functional significance of aberrantly expressed microRNAs in prostate cancer.
- 11 February 2015
- Published by Wiley in International Journal of Urology
- Vol. 22 (3) , 252-3
Editorial comment to Functional significance of aberrantly expressed microRNAs in prostate cancer.